Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rademikibart for Acute Exacerbation of COPD
NCT06940154Phase 2Completed
- Sponsor
- Connect Biopharma
- Start
- Aug 2025
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of rademikibart in chronic obstructive pulmonary disease (COPD), sponsored by Connect Biopharma. Started Aug 2025; status: completed.
02
Drugs
rademikibart
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06940154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06940154.